GT Biopharma (GTBP) an immuno-oncology company focused on innovative treatments for cancer, based on its patent-pending TriKE™ technology has made public a recent study at the University of Minnesota which has confirmed that its HIV-TriKE™ drug platform has successfully killed patient HIV infected cells.
Get Your Free In-Depth Report on GT Biopharma (GTBP)!
Cancer & HIV/AIDS has a major impact on society in the United States and across the world.
Cancer.gov estimates that in 2018 1,735,350 new cases of cancer will be diagnosed & 609,640 people will die from the disease in the United States alone!
The World Health Organization estimates that as of 2017 there were 36.7 million people living with HIV globally with 1.8 million people becoming newly infected and 1 million dead of HIV-related causes.
Earlier this year MarketWatch published an article saying:
“The global oncology drugs market was valued at US$ 77.3 billion in 2018, and is projected to exhibit a CAGR of 12.3% during the forecast period (2018 – 2026).”
If these numbers are correct, this means that the global oncology drugs market could Surpass US$ 196.2 Billion by 2026.
According to an article on Fortune Business Insights” the HIV/AIDS drug market was valued at US$ 25.3 billion in 2018 and according to the website is projected to reach US$ 40.6 billion by the end of 2026 based on a CAGR of 6.1%, between 2019-2026.
Based on this information we are now talking about an industry that is currently worth over US$ 100 billion with the potential in the next 6.5 years to be worth over US$ 200 billion.
This is a Massive Opportunity for Companies In This Space
GT Biopharma (GTBP) is a clinical-stage, immuno-oncology biotech company focused on innovative treatments based on its patent-pending TriKE™ technology. GT Biopharma (GTBP) is in good company within this space.
Obviously you have the biotech giants:
- Gilead Sciences, Inc. (NASDAQ:GILD)
- Incyte Corporation (NASDAQ:INCY)
- Merck & Co. (NYSE:MRK)
But according to a recent article that was published on The Motley Fool it may be time for investors to give their attention to the “little guys” aka the Small Cap Stocks.
Within this article, The Motley Fool talks about 3 “Out of favor” “Cancer Treatment Stocks.” One of the companies is a small-cap stock that, according to the article, “sports marquee oncology partnerships with Gilead Sciences, Incyte, as well as Merck.”
This is a great example of a small-cap company utilizing its relationships with credible, larger entities to forward their corporate missions.
Connecting The Dots
Similarly, when investors look at GT Biopharma (GTBP) they will notice that the company is indeed a small-cap stock and like the company The Motley Fool mentioned, has ties to a large entity to help further its own corporate missions.
GT Biopharma (GTBP) has deep ties to the University of Minnesota & its prestigious Masonic Cancer Center, a comprehensive cancer center designated by the National Cancer Institute.
The University of Minnesota is the site for the current in-human TriKE™ phase 1 clinical trial.
In addition to being the host site for GT Biopharma (GTBP) ’s in-human clinical trial Deputy Director of the University of Minnesota’s Masonic Comprehensive Cancer Center. Dr. Jeffery Miller was hired to be GT Biopharma (GTBP) ’s Consulting Chief Medical Officer in August 2019.
To top it off on September 19, 2019, it was announced on the University of Minnesota’s website that:
University of Minnesota discovery is now a first-in-human clinical trial for leukemia & designer molecule will activate the patient’s own immune cells to attack cancer. The discovery of tri-specific natural killer engagers (TriKE™), a combination protein that bridges an immune cell and a tumor cell to drive tumor cell killing power exponentially, has led to a new Phase I, first-in-human study to treat leukemia. The study is opening exclusively at the University of Minnesota Medical Center and is being sponsored by GT Biopharma, Inc.
The relationship that GT Biopharma (GTBP) builds with the University of Minnesota and its Consulting Chief Medical Officer Dr. Jeffrey Miller continues to be a fruitful one.
On October 3, 2019 GT Biopharma (GTBP) announced that Tim Schacker, M.D., Jeffrey S. Miller, M.D., and their colleagues at the University of Minnesota presented data during a poster session held at the 18th meeting of the Society for Natural Immunity in Luxembourg discussing their design of an HIV-TriKE™ containing an antigen-binding fragment (Fab) from a broadly-neutralizing antibody targeting the HIV-Env protein. The HIV-TriKE™ is designed to target HIV while redirecting NK cell killing specifically to actively replicating HIV infected cells.
Mr. Anthony Cataldo, the Chairman and Chief Executive Officer of GT Biopharma, commented, “We are pleased to see how the TriKE™ technology is able to be extended to the treatment of infectious disease, and is able to kill HIV in the reservoir.” Mr. Cataldo further stated, “We believe the HIV-TriKE™ will become part of a scalable and curative therapeutic strategy.”
Get Your Free In-Depth Report on GT Biopharma (GTBP)!
How Does GT Biopharma (GTBP) Measure Up Against the Competition?
GT Biopharma (GTBP) Is Developing Treatments That Stand Head-To-Head With Some Of The Industry’s Top Companies
A unique opportunity could be presenting itself for GT Biopharma (GTBP) to far surpass some of the industry’s biggest companies.
The key to this opportunity is within the use of NK cells versus the standard “T-Cell” treatment methods.
Lose You?
Don’t Worry We’ll Explain Further…
Amgen (AMGN) – $175 Million Revenue Potential
Amgen’s T-cell cell engager was approved for marketing in December 2014. Under the branded treatment, Blincyto, Amgen’s treatment targets patients with specific types of leukemia. Where this treatment is based on T-cell therapy, it needs to activate the body’s immune system first, which could present its own list of risks. In comparison, GT BIopharma’s TriKEs/TetraKEs engage NK cells which may have potential advantages as there’s no need to “prime” the immune system. The bottom line is that even in this case, the more archaic T-cell treatment helped generate $175 million in sales in 2017 for Amgen’s Blincyto.
Gilead (GILD) And Its Acquisition of Kite Pharma – Buyout Valued At $11.9 Billion
In October 2017, Kite Pharma’s (previously publicly traded as “KITE”) therapy, Yescarta became the first CAR-T therapy approved by the FDA for the treatment of adult patients with certain types of lymphoma after two or more lines of systemic therapy. Based on this development, one of the mega-industry leaders, Gilead (GILD) bought out the company for a cool $11.9 Billion. As with the Amgen case, GT Biopharma (GTBP) NK cell platform poses even more opportunity beyond the simple T-Cell or “CAR-T” cell treatment as targeted therapies begin to take a more prominent place in cancer and immuno-oncology treatment.
Affimed (AFMD) & Roche (RHHBY) Collaboration Through Genentech – $5.9 Billion Deal
Clinical stage biopharmaceutical company Affimed (AFMD) inked a deal with a potential value of nearly $6 billion with Roche (RHHBY) company, Genentech. This is one of the clearest examples of the potential of NK cell platforms. Because these “engager-based” immunotherapeutics can treat multiple cancers, the therapies can be tailor-made for patients without having to “pre-stimulate” the body’s immune system. Not only did Affimed get an upfront payment of $96 million but with milestones, it can receive up to another $5 billion.
Meet The GT Biopharma (GTBP) Management Team
GT Biopharma (GTBP) has a management team comprised of the biotech sector’s biggest, brightest and most successful.
[block id=”4858″ title=”GTBP Team”] [block id=”4811″ title=”In The News”]How Does GT Biopharma (GTBP) Measure Up Against the Competition?
- GT Biopharma (GTBP) is operating within a space that is currently valued at US$ 100 billion and is estimated to be valued at US$ 200 billion by 2026. This is a massive growth opportunity.
- GT Biopharma (GTBP) has made public a recent study at the University of Minnesota which has confirmed that its HIV-TriKE™ drug platform has successfully killed patient HIV infected cells.
- GT Biopharma’s (GTBP) deep ties with the University of Minnesota & its Masonic Cancer Center, its Deputy Director & now GT Biopharma’s (GTBP) Consulting Chief Medical Officer Dr. Jeffery Miller give the company a huge advantage.
- GT Biopharma (GTBP) is developing treatments that stand head-to-head with some of the industry’s top companies.
- GT Biopharma (GTBP) has a management team comprised of some of the biggest, brightest and most successful professionals within the biotech sector.
Get Your Free In-Depth Report on GT Biopharma (GTBP)!
Sources
https://www.fortunebusinessinsights.com/industry-reports/hiv-aids-drugs-market-101115
https://www.cancer.gov/about-cancer/understanding/statistics
https://www.who.int/features/qa/71/en/
https://www.fool.com/investing/2019/10/10/3-cancer-treatment-stocks-to-buy-right-now.aspx
https://www.cancer.umn.edu/node/17706https://finance.yahoo.com/quote/GTBP?p=GTBP&.tsrc=fin-srch
Disclaimer:
Pursuant to an agreement between Midam Ventures LLC and GT Biopharma (GTBP), Midam has been paid $100,000 for a period from October 1, 2019 to November 15, 2019. We may buy or sell additional shares of GT Biopharma (GTBP) in the open market at any time, including before, during or after the Website and Information, to provide public dissemination of favorable Information about GT Biopharma (GTBP). Click Here For Full Disclaimer.
